Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
JAGSNPHARM.NS
Strong BuyPremium GrowerJagsonpal Pharmaceuticals Limited · Healthcare · India · $165M · Avg Vol: $1M/d
94
StockRankGet insider-trade alerts
Q
81
V
36
M
81
P/E (TTM)
35.1x
ROE
15.6%
D/E
0.0x
Dividend %
2.8%
COMPANY DESCRIPTION
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2.4B | 2.1B | 2.7B | 2.9B | 6.7% | 2.9B |
| EPS (INR) | 4.08 | 3.40 | 8.26 | 6.40 | 16.2% | 6.72 |
| Shares | 65.5M | 66.1M | 66.4M | 67.0M | +2.2% | 66.0M |
| Debt | 60.0M | 89.4M | 92.4M | 81.7M | 10.8% | 81.9M |
| Equity | 1.6B | 1.9B | 2.4B | 2.8B | 20.2% | — |
| Op CF | 466.6M | 351.7M | 551.1M | 468.1M | 0.1% | 469.7M |
| Inv CF | -576.7M | -245.5M | -451.5M | -356.5M | — | — |
| Fin CF | -4.6M | -89.1M | -117.0M | -121.5M | — | — |
Loading 1Y...
PRICE (1Y)+3.8%
SMA 50SMA 200
Close
$2.47
RSI (14)
61.1
52W High
$2.73
From 52W High
0.9%
SCORE BREAKDOWN
Quality
81
ROIC
21.4%91.3
ROE
15.6%83.1
GP/Assets
59.3%90.9
Op. Margin
18.4%80.6
FCF/Assets
14.7%93.4
Piotroski
431.0
Int. Cover
50.0x89.2
D/E Ratio
0.03x76.1
Current Ratio
5.06x72.5
Value
36
P/E (TTM)
35.1x33.6
EV/EBITDA
23.7x27.9
P/FCF
33.7x43.1
P/B
6.0x23.1
P/S
5.3x40.2
Div Yield
2.8%66.0
Momentum
81
52W High %
90%86.1
RS 6M
40%89.0
SMA 50/200
1.14x82.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
22%57.2
FUNDAMENTALS
Market Cap
$165M
P/E (Forward)
—
Gross Margin
63.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JAGSNPHARM.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited(you) | $165M | 94 | Strong Buy |
| SYNCOMF.NS | Syncom Formulations (India) Limited | $208M | 95 | Strong Buy |
| LINCOLN.NS | Lincoln Pharmaceuticals Limited | $135M | 99 | Strong Buy |
| ANUHPHR.NS | Anuh Pharma Limited | $101M | 95 | Strong Buy |
| VENUSREM.NS | Venus Remedies Limited | $229M | 99 | Strong Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| ALBERTDAVD.NS | Albert David Limited | $51M | 93 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%